HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT01566162

Long-Term Lurasidone Safety for Schizophrenia

About this title

A Twelve Week, Open Label Extension Study in Patients With Schizophrenia

Read the official source — NCT01566162
Medication studyAges 18+Multiple countries
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Listed locations
Little Rock and 62 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study clarity

Study information

Study start dateApril 2012
Recruitment status
Completed
Enrollment listed in the registry
191
Sponsor
Sumitomo Pharma America, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, France, Italy, ...
Age range
Over 18 Years
Official registry ID
NCT01566162
Official title
Show the full official title

A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Little Rock, United States · Cerritos, United States · Downey, United States

55 more locations
  • Escondido, United States
  • Garden Grove, United States
  • Los Angeles, United States
  • National City, United States
  • Oceanside, United States
  • Pico Rivera, United States
  • San Diego, United States
  • Santa Ana, United States
  • Torrance, United States
  • Bradenton, United States
  • Kissimmee, United States
  • Miami Springs, United States
  • Orange City, United States
  • Atlanta, United States
  • Lake Charles, United States
  • Shreveport, United States
  • Rockville, United States
  • O'Fallon, United States
  • St Louis, United States
  • Las Vegas, United States
  • Willingboro, United States
  • Buffalo, United States
  • Cedarhurst, United States
  • Fresh Meadows, United States
  • Rochester, United States
  • Oklahoma City, United States
  • Philadelphia, United States
  • Lincoln, United States
  • Austin, United States
  • Dallas, United States
  • Salt Lake City, United States
  • Dole, France
  • Toulon, France
  • Massa, Italy
  • Pisa, Italy
  • Lipetsk, Russia
  • Rostov-on-Don, Russia
  • Saint Peterburg, Russia
  • Saint Petersburg, Russia
  • Belgrade, Serbia
  • Dusica, Serbia
  • Kragujevac, Serbia
  • Niš, Serbia
  • Novi Kneževac, Serbia
  • Novi Sad, Serbia
  • Bojnice, Slovakia
  • Bratislava, Slovakia
  • Michalovce, Slovakia
  • Rimavská Sobota, Slovakia
  • Rožňava, Slovakia
  • Svidník, Slovakia
  • Tygervalley, South Africa
  • Bloemfontein, South Africa
  • Pretoria, South Africa
  • Russia
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Lurasidone.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies